|1.||Schuetz, Philipp: 13 articles (06/2015 - 01/2011)|
|2.||Mueller, Beat: 7 articles (06/2015 - 01/2011)|
|3.||Struck, Joachim: 7 articles (01/2014 - 07/2009)|
|4.||Morgenthaler, Nils G: 6 articles (07/2012 - 08/2007)|
|5.||Bergmann, Andreas: 6 articles (03/2012 - 08/2007)|
|6.||Müller, Beat: 5 articles (01/2015 - 01/2013)|
|7.||Albrich, Werner C: 5 articles (01/2014 - 01/2011)|
|8.||Huber, Andreas: 4 articles (01/2015 - 01/2013)|
|9.||Blankenberg, Stefan: 4 articles (10/2014 - 01/2012)|
|10.||Zeller, Tanja: 4 articles (10/2014 - 01/2012)|
|1.||Respiratory Tract Infections (Respiratory Tract Infection)
11/29/2012 - "The aim of this study was to determine the prognostic utility of serial measurement of the cardiovascular biomarker midregion proadrenomedullin (MR-proADM) in patients admitted with lower respiratory tract infection. "
01/01/2014 - "A pilot study on the diagnostic accuracy of proadrenomedullin and proatrial natriuretic Peptide in lower respiratory tract infections."
11/29/2012 - "Time-dependent Cox regression: serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection."
01/01/2011 - "Proadrenomedullin (ProADM) confers additional prognostic information to established clinical risk scores in lower respiratory tract infections (LRTI). "
01/01/2011 - "Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm."
07/01/2012 - "Plasma midregional proadrenomedullin in newborn infants: impact of prematurity and perinatal infection."
12/01/2014 - "The area under the receiver operating characteristic curve for bloodstream infection diagnosis was significantly greater for proadrenomedullin (0.70; 95% CI, 0.59-0.82) and procalcitonin (0.71; 95% CI, 0.60-0.83) compared with C-reactive protein (0.53; 95% CI, 0.39-0.66) (p = 0.021 and p = 0.003, respectively). "
12/01/2014 - "In patients with documented infections, proadrenomedullin (0.81; 95% CI, 0.71-0.92) and procalcitonin (0.73; 95% CI, 0.60-0.85) each had a greater area under the curve compared with C-reactive protein (0.59; 95% CI, 0.45-0.73) as for as predicting response (p = 0.004 and p = 0.043, respectively). "
12/01/2014 - "In critically ill patients with cancer, proadrenomedullin and procalcitonin both have a promising role in predicting bloodstream infections in a manner more helpful than C-reactive protein. "
01/01/2014 - "New biomarkers such as those in this review will discuss the major types of biomarkers of bloodstream infections/sepsis, including soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), soluble urokinase-type plasminogen receptor (suPAR), proadrenomedullin (ProADM), and presepsin. "
|3.||Bacterial Infections (Bacterial Infection)
08/01/2012 - "Markers such as lactate for risk stratification and guidance of fluid resuscitation, procalcitonin for assessing risk of bacterial infections and guiding therapeutic decisions about initiation and duration of antimicrobial therapy, and recently proadrenomedullin for early mortality prediction and site-of-care decisions in respiratory infections, have shown to improve patient management. "
01/01/2015 - "Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study."
09/01/2015 - "Proadrenomedullin (proADM), a cardiovascular biomarker, has shown high prognostic power for community-acquired pneumonia (CAP) outcomes. "
01/01/2015 - "Proadrenomedullin median values increased more than twofold, in complicated vs. uncomplicated (0.18 vs. 0.08 nmol/L, p = 0.039), and fivefold in bacteremic vs. non-bacteremic pneumonia (0.40 vs. 0.08 nmol/L, p = 0.02). "
01/01/2015 - "midregional proadrenomedullin (MR-proADM) is a prognostic biomarker in patients with community-acquired pneumonia (CAP). "
01/01/2015 - "Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia."
01/01/2012 - "Midregional proadrenomedullin (MR-proADM) is a newly identified prognostic marker in heart failure. "
03/15/2014 - "Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study."
03/01/2015 - "The influence of diabetes mellitus on midregional proadrenomedullin concentrations and prognostic value in heart failure outpatients."
03/01/2013 - "Elevated levels of plasma ET-1 and ADM, and their biologically stable surrogates, C-terminal-pro-endothelin-1 (CT-pro-ET-1) and midregional proadrenomedullin (MR-pro-ADM), are predictors of cardiac death and heart failure. "
07/01/2012 - "Midregional proadrenomedullin (MR-proADM) is elevated in patients with heart failure and myocardial infarction. "
|4.||Biological Markers (Surrogate Marker)
|7.||Growth Differentiation Factor 15
|9.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|10.||Uric Acid (Urate)
|2.||Length of Stay
|4.||Extracorporeal Membrane Oxygenation (ECMO)